P53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease

Journal of Neuro-Oncology

Volumn 106, Issue 1, 2012, Pages 135-141

  Gessi, Marco ^a   Von Bueren, André O ^b   Rutkowski, Stefan ^b   Pietsch, Torsten ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

catenin; Immunohistochemistry; Medulloblastoma; Metastasis; p53; TP53 mutations

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE; GERMANY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; METASTASIS; MULTICENTER STUDY; OVERALL SURVIVAL; POINT MUTATION; PREDICTION; PRESCHOOL CHILD; PROGNOSIS; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; TP53 GENE;

ADOLESCENT; BETA CATENIN; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MEDULLOBLASTOMA; MUTATION; NEOPLASM METASTASIS; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PREDICTIVE VALUE OF TESTS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 83055194621     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0648-8     Document Type: Article

References (32)

1. Giangaspero F, Eberhart CG, Haapasalo HH, Pietsch T, Wiestler OD, Ellison DW (2007) Medulloblastoma. In: Louis DN, Ohgaki H, Wiestler OD (eds) WHO Classification of Tumours of the Central Nervous System, 4th edn. IARC press, Lyon, pp 132-140
2. DW Ellison 2010 Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease Acta Neuropathol 120 305 316 20652577 10.1007/s00401-010-0726-6
3. RJ Packer BR Rood TJ MacDonald 2003 Medulloblastoma: present concepts of stratification into risk groups Pediatr Neurosurg 39 60 67 12845195 10.1159/000071316 (Pubitemid 36829097)
4. S Rutkowski K von Hoff A Emser, et al. 2010 Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis J Clin Oncol 28 4961 4968 20940197 10.1200/JCO.2010.30.2299
5. PM Zeltzer JM Boyett JL Finlay, et al. 1999 Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study J Clin Oncol 17 832 845 10071274 1:CAS:528:DyaK1MXhvFGgur0%3D (Pubitemid 29109313)
6. JA Royds B Iacopetta 2006 p53 and disease: when the guardian angel fails Cell Death Differ 6 1017 1026 10.1038/sj.cdd.4401913
7. A Machado-Silva S Perrier JC Bourdon 2010 p53 family members in cancer diagnosis and treatment Semin Cancer Biol 20 57 62 20206267 10.1016/j.semcancer. 2010.02.005 1:CAS:528:DC%2BC3cXlsFSitr4%3D
8. CG Eberhart A Chaudhry RW Daniel L Khaki KV Shah PE Gravitt 2005 Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus BMC Cancer 5 19 15717928 10.1186/1471-2407-5-19 (Pubitemid 41461108)
9. R Miralbell M Tolnay S Bieri, et al. 1999 Pediatric medulloblastoma: prognostic value of p53, bcl-2, Mib-1, and microvessel density J Neurooncol 45 103 110 10778725 10.1023/A:1006330324991 1:STN:280:DC%2BD3c3jvV2qtA%3D%3D (Pubitemid 30197723)
10. DH Nam KC Wang YM Kim, et al. 2000 The effect of isochromosome 17q presence, proliferative and apoptotic indices, expression of C-erbB-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma J Korean Med Sci 15 452 456 10983696 1:CAS:528:DC%2BD3cXmvVenu7s%3D
11. RT Wooburn B Azzarelli JF Montebello IE Goss 2001 Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors J Neuro-oncol 52 57 62 10.1023/A:1010691330670 (Pubitemid 32544659)
12. A Ray M Ho J Ma, et al. 2004 A clinicobiological model predicting survival in medulloblastoma Clin Cancer Res 10 7613 7620 15569993 10.1158/1078-0432.CCR-04-0499 1:CAS:528:DC%2BD2cXhtVanurzP (Pubitemid 39557524)
13. E Jaros J Lunec RH Perry, et al. 1993 p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis Br J Cancer 68 801 807 8398711 10.1038/bjc.1993.431 1:STN:280:DyaK2c%2FgtFCrtg%3D%3D (Pubitemid 23301290)
14. TJ MacDonald KM Brown B LaFleur, et al. 2001 Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease Nat Genet 2 143 152 10.1038/ng731 (Pubitemid 32952650)
15. E Pfaff M Remke D Sturm, et al. 2010 TP3 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma J Clin Oncol 28 5188 5196 21060032 10.1200/JCO.2010.31.1670 1:CAS:528:DC%2BC3MXhtlaktLk%3D
16. U Tabori B Baskin M Shago, et al. 2010 Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations J Clin Oncol 28 1345 1350 20142599 10.1200/JCO.2009.23.5952 1:CAS:528:DC%2BC3cXksFSqtbY%3D
17. JC Lindsey RM Hill H Megahed, et al. 2011 TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas J Clin Oncol 29 344 346 10.1200/JCO.2010.33.8590
18. CH Chang EM Housepian C Herbert Jr 1969 An operative staging system and a megavoltage radiotherapeutic technique for cerebellar medulloblastomas Radiology 93 1351 1359 4983156 1:STN:280:DyaE3c%2FnvVOhtQ%3D%3D
19. S Rutkowski U Bode F Deinlein, et al. 2005 Treatment of early childhood medulloblastoma by postoperative chemotherapy alone N Engl J Med 352 978 979 15758008 10.1056/NEJMoa042176 1:CAS:528:DC%2BD2MXit1WksLs%3D (Pubitemid 40349500)
20. JA Kraus C Bolln HK Wolf, et al. 1994 TP53 alterations and clinical outcome in low grade astrocytomas Genes Chromosomes Cancer 10 143 149 7520269 10.1002/gcc.2870100211 1:CAS:528:DyaK2MXjsVCntQ%3D%3D (Pubitemid 24155986)
21. JA Kraus J Felsberg JC Tonn G Reifenberger T Pietsch 2002 Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood Neuropathol Appl Neurobiol 28 325 333 12175345 10.1046/j.1365-2990.2002.00413.x 1:CAS:528:DC%2BD38XnsVSnur0%3D (Pubitemid 34989295)
22. A Koch A Waha JC Tonn, et al. 2001 Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors Int J Cancer 93 445 449 11433413 10.1002/ijc.1342 1:CAS:528:DC%2BD3MXlt12gtr4%3D (Pubitemid 32592067)
23. S Rutkowski A von Bueren K von Hoff, et al. 2007 Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91 Clin Cancer Res 13 2651 2657 17473196 10.1158/1078-0432.CCR-06-1779 1:CAS:528:DC%2BD2sXkslOhtbg%3D (Pubitemid 46788032)
24. A Waha M Watzka A Koch, et al. 1998 A rapid and sensitive protocol for competitive reverse transcriptase (cRT) PCR analysis of cellular genes Brain Pathol 8 13 18 9458162 10.1111/j.1750-3639.1998.tb00129.x 1:CAS:528: DyaK1cXjs1Ohu7s%3D (Pubitemid 28055760)
25. EL Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481 10.2307/2281868
26. AI Robles CC Harris 2010 Clinical outcomes and correlates of TP53 mutations and cancer Cold Spring Harb Perspect Biol 2 1 15 10.1101/cshperspect. a001016
27. HS Min YJ Lee K Park BK Cho SH Park 2006 Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior Acta Neuropathol 112 13 20 16691420 10.1007/s00401-006-0073-9 1:CAS:528:DC%2BD28Xmt1Oksr0%3D (Pubitemid 43942158)
28. AJ Frank R Hernan A Hollander, et al. 2004 The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma Brain Res Mol Brain Res 121 137 140 14969745 10.1016/j.molbrainres.2003.11.016 1:CAS:528:DC%2BD2cXht1yktb0%3D (Pubitemid 38224178)
29. SW Lowe S Bodis A McClatchey, et al. 1994 p53 status and the efficacy of cancer therapy in vivo Science 266 807 810 7973635 10.1126/science.7973635 1:CAS:528:DyaK2MXitVGgt7w%3D (Pubitemid 24359290)
30. JT Huse EC Holland 2009 Genetically engineered mouse models of brain cancer and the promise of preclinical testing Brain Pathol 19 132 143 19076778 10.1111/j.1750-3639.2008.00234.x 1:CAS:528:DC%2BD1MXitVWht70%3D
31. AM Adesina J Nalbantoglu WK Cavenee 1994 p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma Cancer Res 54 5649 5651 7923211 1:CAS:528:DyaK2cXmvFyitrc%3D
32. RC Castellino M De Bortoli X Lu, et al. 2008 Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D J Neurooncol 86 245 256 17932621 10.1007/s11060-007-9470-8 1:CAS:528:DC%2BD1cXivVKrsbw%3D